A leading pharmaceutical manufacturer has secured a significant international contract, marking a major milestone in global healthcare initiatives. The company will supply 115 million doses of crucial bivalent oral polio vaccine to UNICEF in 2025, in a deal valued at approximately Rs. 127 crore, strengthening its position in the global vaccine market.
Share Price Movement
The share price of Panacea Biotec Limited hit the upper circuit of 5 percent to Rs. 454.9 per share on Thursday, an increase from its previous close of Rs. 433.25 per share. The market capitalisation now stands at approximately Rs. 2,742.5 crore as of December 26, 2024.
Contract Details
Panacea Biotec Limited has received a Letter of Award from UNICEF to supply 115 million doses of bivalent oral polio vaccine (bOPV) worth approximately US$ 14.95 million ( Rs. 127 crore) in 2025. The contract is part of UNICEF’s international efforts to meet vaccine demands in Africa and Asia.
Q2 Financial Highlights
According to its recent filing, in the quarter ending September 2024, Panacea Biotec’s consolidated revenue from operations has increased by 2.8 percent YOY from Rs. 143 crore in Q2 FY24 to Rs. 147 crore in Q2 FY25 and decreased by 26.7 percent QoQ from Rs. 116 crore in Q4 FY24.
The company’s consolidated net loss went from a loss of Rs. 8.3 crore in Q2 FY24 to a profit of Rs. 4.7 crore in Q2 FY25.
Market Outlook
The Indian vaccine industry is experiencing robust growth, fuelled by rising demand, government initiatives, and increased awareness. The sector benefits from strong support through awareness programs, regulatory ease, and foreign investments. India remains a global leader in vaccine production, supplying 60% of global vaccines.
The market is projected to grow from Rs. 29,000 crore in 2023 to Rs. 99,600 crore by 2030, with a CAGR of 10-12%. Advancements in technology, manufacturing capacity, and government-led programs will further drive growth in this sector.
Also read….
Shareholding Pattern
As of the September 2024 shareholding pattern, Panacea Biotec Limited is primarily held by the promoters at 72.87 percent, foreign institutional investors hold 0.37 percent, and the public with 25.6 percent.
About Company
Founded in 1984, Panacea Biotec Limited is a leading pharmaceutical and biotechnology company based in New Delhi, India. Listed publicly since 1995, the company specialises in developing, manufacturing, and marketing vaccines, biosimilars, pharmaceutical formulations, and nutraceuticals. With a workforce of around 1,150 employees, Panacea Biotec operates offices in New Delhi, Mumbai, and Lalru, near Chandigarh.
The company is renowned for its extensive vaccine portfolio, which includes EasySix, EasyFive-TI, and the Bivalent Oral Polio Vaccine. Additionally, Panacea Biotec continues to innovate with vaccines such as NucoVac 11 and DengiALL. Its pharmaceutical offerings include Sitcom Tablets and Cream, along with nutritional products like ChilRunfull. Despite facing challenges, including the 2011 removal of some vaccines from the WHO’s list, the company rebounded swiftly, regaining its status by 2013.
Panacea Biotec remains focused on oncology, nephrology, gastroenterology, and diabetes. By advancing healthcare solutions, the company aims to enhance global access to affordable treatments.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
